8. Huntington disease Clinical trials / Disease details
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02101957 (ClinicalTrials.gov) | October 2010 | 25/3/2014 | Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103) | Huntington's Disease | Drug: RP103;Drug: Placebo | University Hospital, Angers | NULL | Active, not recruiting | 18 Years | 65 Years | Both | 96 | Phase 2/Phase 3 | France | |
| 2 | EUCTR2010-019444-39-FR (EUCTR) | 18/06/2010 | 04/05/2010 | Essai multicentrique de traitement de la maladie de Huntington par la cystéamine - CYST-HD | Essai multicentrique de traitement de la maladie de Huntington par la cystéamine - CYST-HD | Maladie de Huntington. MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea | Product Name: Cysteamine Bitartrate Product Code: RP 103 | Centre Hospitalier Universitaire d'Angers | NULL | Not Recruiting | Female: yes Male: yes | 96 | Phase 2;Phase 3 | France |